Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865656 | 0.93 | NPY5R (0.33) | NPY5RALDH1A1MAPTEPHX2KMT2A | |
| SCHEMBL2862859 | 0.82 | HTR2A (0.33) | NPY5RALDH1A1MAPTEPHX2KMT2A | |
| SCHEMBL2864645 | 0.81 | KDM4E (0.32) | NPY5RALDH1A1MAPTEPHX2KMT2A | |
| SCHEMBL2861354 | 0.75 | NPSR1 (0.49) | ALDH1A1MAPTHTTKCNN4KMT2A | |
| Hydrochloric Acid SCHEMBL2861673 | 0.75 | NPSR1 (0.35) | ALDH1A1MAPTKCNN4KMT2A | |
| SCHEMBL2862002 | 0.72 | CACNA1G (0.42) | KMT2A | |
| SCHEMBL2856685 | 0.72 | NPSR1 (0.49) | ALDH1A1KCNN4KMT2A | |
| Hydrochloric Acid SCHEMBL2869159 | 0.71 | NPSR1 (0.35) | ALDH1A1MAPTKMT2A | |
| SCHEMBL2864543 | 0.70 | POLB (0.38) | KCNN4KMT2A | |
| SCHEMBL2869730 | 0.69 | SIGMAR1 (0.43) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | NPY5R 339/4885ALDH1A1 2926/4885MAPT 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.